ArticleAntimicrobial agents and chemotherapy2013
Discovery of antivirulence agents against methicillin-resistant Staphylococcus aureus.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.
- Proportion of toxin and non-toxin virulence factors of Staphylococcus aureus isolates from diabetic foot infection: a systematic review and meta-analysis.BMC microbiology · 2024Pooled it
- The spectrum of nasal colonization: frequency and resistant patterns in diabetes versus non-diabetes population.BMC microbiology · 2026Article
- Hijacking the signal: a critical evaluation of quorum sensing inhibitors as a next-generation approach against Staphylococcus aureus.Cell communication and signaling : CCS · 2026Review
- Research Progress on Antivirulence Agents Targeting the Accessory Gene Regulator (Agr) System ofInfection and drug resistance · 2026Review
- Repurposing Diflunisal as an Antivirulence Agent AgainstInfectious microbes & diseases · 2025Article
- The anti-biofilm compound 4-ethoxybenzoic acid inhibitsFrontiers in microbiology · 2025Article
- Forssman and the staphylococcal hemolysins.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Review
- Drug Repurposing: Insights into Current Advances and Future Applications.Current medicinal chemistry · 2025Review
- Deciphering agr quorum sensing in Staphylococcus aureus: insights and therapeutic prospects.Molecular biology reports · 2024Review
- Physalin H, physalin B, and isophysalin B suppress the quorum-sensing function ofFrontiers in pharmacology · 2024Article
- Exploring diflunisal as a synergistic agent againstFrontiers in microbiology · 2024Article
- Repurposed Fenoprofen Targeting SaeR AttenuatesACS central science · 2023Article
- Diflunisal and Analogue Pharmacophores Mediating Suppression of Virulence Phenotypes inAntibiotics (Basel, Switzerland) · 2023Article
- Chemical and biomolecular insights into theIsrael journal of chemistry · 2023Article
- Diclofenac and Meloxicam Exhibited Anti-Virulence Activities Targeting Staphyloxanthin Production in Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Neutralization of Staphylococcus aureus Protein A Prevents Exacerbated Osteoclast Activity and Bone Loss during Osteomyelitis.Antimicrobial agents and chemotherapy · 2023Article
- The Cell Wall, Cell Membrane and Virulence Factors ofMicroorganisms · 2023Review
- The role of bacterial signaling networks in antibiotics response and resistance regulation.Marine life science & technology · 2022Review
- The promising anti-virulence activity of candesartan, domperidone, and miconazole on Staphylococcus aureus.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Article
- Alternative Treatment Strategies for Secondary Bacterial and Fungal Infections Associated with COVID-19.Infectious diseases and therapy · 2022Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Antivirulence agents inhibit the production of disease-causing virulence factors but are neither bacteriostatic nor bactericidal. Antivirulence agents against methicillin-resistant Staphylococcus aureus (MRSA) strain USA300, the most widespread community-associated MRSA strain in the United States, were discovered by virtual screening against the response regulator AgrA, which acts as a transcription factor for the expression of several of the most prominent S. aureus toxins and virulence factors involved in pathogenesis. Virtual screening was followed by similarity searches in the databases of commercial vendors. The small-molecule compounds discovered inhibit the production of the toxins alpha-hemolysin and phenol-soluble modulin α in a dose-dependent manner without inhibiting bacterial growth. These antivirulence agents are small-molecule biaryl compounds in which the aromatic rings either are fused or are separated by a short linker. One of these compounds is the FDA-approved nonsteroidal anti-inflammatory drug diflunisal. This represents a new use for an old drug. Antivirulence agents might be useful in prophylaxis and as adjuvants in antibiotic therapy for MRSA infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.